| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/09/2005 | CA2546863A1 Chaperone-based therapy for niemann-pick disease |
| 06/09/2005 | CA2546664A1 Anti-igfr1 antibody therapeutic combinations |
| 06/09/2005 | CA2546637A1 Colonic purgative composition with soluble binding agent |
| 06/09/2005 | CA2546395A1 Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| 06/09/2005 | CA2546366A1 Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders |
| 06/09/2005 | CA2546360A1 Methods of treating diseases and disorders by targeting multiple kinases |
| 06/09/2005 | CA2545655A1 Combination drug therapy to treat obesity |
| 06/09/2005 | CA2536188A1 Electrical devices and anti-scarring agents |
| 06/09/2005 | CA2536181A1 Polymer compositions and methods for their use |
| 06/08/2005 | EP1537878A1 Immunopotentiating compositions |
| 06/08/2005 | EP1537869A2 Radiosensibilizer and preparation thereof |
| 06/08/2005 | EP1537861A2 Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation |
| 06/08/2005 | EP1537857A1 Mupirocin compositions for topical use, a process of making same and uses thereof |
| 06/08/2005 | EP1537417A2 Method of diagnosing colon and gastric cancers |
| 06/08/2005 | EP1537243A1 Method of diagnosing ovarian endometriosis |
| 06/08/2005 | EP1537237A2 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 06/08/2005 | EP1537208A1 Non-sequence complementary antiviral oligonucleotides |
| 06/08/2005 | EP1537205A2 Viral deconstruction through capsid assembly in vitro |
| 06/08/2005 | EP1537138A2 Receptors and membrane-associated proteins |
| 06/08/2005 | EP1537079A2 PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| 06/08/2005 | EP1537074A1 Cathepsin cysteine protease inhibitors |
| 06/08/2005 | EP1536863A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 06/08/2005 | EP1536845A1 Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| 06/08/2005 | EP1536839A2 Method for treating diseases with omega interferon |
| 06/08/2005 | EP1536834A2 Design of chemokine analogs for the treatment of human diseases |
| 06/08/2005 | EP1536818A2 Fibrinogen binding moieties |
| 06/08/2005 | EP1536812A2 Methods for modulating activity of the fxr nuclear receptor |
| 06/08/2005 | EP1536804A2 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 06/08/2005 | EP1536801A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 06/08/2005 | EP1536797A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related comounds as neurokinin-1 (nk-1) antagonsists for the treatment of emesis, depression, anxiety and cough |
| 06/08/2005 | EP1536793A1 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
| 06/08/2005 | EP1536781A1 Nutritional or pharmaceutical compositions for increasing the creatine response of organisms |
| 06/08/2005 | EP1536778A2 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/08/2005 | EP1536777A1 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 06/08/2005 | EP1536684A2 Method for the prevention and/or treatment of atherosclerosis |
| 06/08/2005 | EP1408981A4 Methods for preventing antipsychotic-induced weight gain |
| 06/08/2005 | EP1373269B1 Jun kinase inhibitors |
| 06/08/2005 | EP1370528B1 Mch antagonists and their use in the treatment of obesity |
| 06/08/2005 | EP1239844B1 Process for producing nanometer particles by fluid bed spray-drying |
| 06/08/2005 | EP1231925B1 Method and composition for the treatment of adenoviral ocular infections |
| 06/08/2005 | EP1223971B1 Compositions for preventing and treating transplant rejection |
| 06/08/2005 | EP1189895B1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 06/08/2005 | EP1024806B1 Use of non-immunosuppressive compounds for promoting nerve regeneration |
| 06/08/2005 | EP0922029B1 Ether muscarinic antagonists |
| 06/08/2005 | EP0784471B1 Multi-faceted method to repress reproduction of latent viruses in humans and animals |
| 06/08/2005 | CN1625603A Genetic polymorphisms in the preprotachykinin gene |
| 06/08/2005 | CN1625569A Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments |
| 06/08/2005 | CN1625565A Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
| 06/08/2005 | CN1625558A Aza-arylpiperazines |
| 06/08/2005 | CN1625557A Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
| 06/08/2005 | CN1625556A Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions |
| 06/08/2005 | CN1625553A Treatment of male sexual dysfunction |
| 06/08/2005 | CN1625412A Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders |
| 06/08/2005 | CN1625411A Combination of a NSAID and a PDE-4 inhibitor |
| 06/08/2005 | CN1625408A Improved kavalactone profile |
| 06/08/2005 | CN1625407A Medicine composition comprising arsenite for treatment of malignancy |
| 06/08/2005 | CN1625406A Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 06/08/2005 | CN1625405A Combinations comprising cox-2 inhibitors and aspirin |
| 06/08/2005 | CN1625404A Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| 06/08/2005 | CN1625398A A combination treatment for acute myocardial infarction |
| 06/08/2005 | CN1625395A Lutein/zeaxanthin for glare protection |
| 06/08/2005 | CN1625393A Alpha 2 delta ligands to treat tinnitus |
| 06/08/2005 | CN1625385A Lipase inhibiting composition |
| 06/08/2005 | CN1205176C Stable salts of o-acetylsalicyclic with basic amino acids |
| 06/08/2005 | CN1204922C Ophthalmic compositions |
| 06/08/2005 | CN1204879C Transdermal therapeutic system wit hneutralized pressure sensitivity acrylic adhesive patch |
| 06/08/2005 | CN1204819C Fat or oil compsn. |
| 06/07/2005 | US6903216 Antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias, atrial fibrillation (AF) or atrial flutter; potassium channel modulators, beta-blocker |
| 06/07/2005 | US6903204 Polynucleotides encoding methionyl tRNA synthetase from Staphylococcus aureus, related products and methods |
| 06/07/2005 | US6903131 Administering to a patient an antiangiogenesis or anticancer agent (N,N-disubstituted-3,4-diamino-2,4-dione-pyrroline derivatives for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer |
| 06/07/2005 | US6903130 (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide stereoisomer for the treatment of bipolar disorders |
| 06/07/2005 | US6903127 Sexual disorders |
| 06/07/2005 | US6903123 Antitussive agents, anxiolytic agents, analgesics for treating cough, anxiety and pain |
| 06/07/2005 | US6903121 Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 06/07/2005 | US6903100 Administering methotrexate at high level to cross the blood brain barrier; methotrexate administration is accompanied by leucovorin rescue of the periphery |
| 06/07/2005 | US6903089 Lactam-substituted pyrazolopyridine derivatives |
| 06/07/2005 | US6903081 Phosphoramidates and methods therefor |
| 06/07/2005 | US6902908 Polypeptides, fusion proteins; includes production and use recombinant expression constructs having regulated promoter; mitochondria |
| 06/07/2005 | US6902738 Topical oral dosage forms containing bismuth compounds |
| 06/07/2005 | US6902734 Also an IL-12 anti-idiotype antibody to the antibody |
| 06/07/2005 | US6902728 For treating or preventing rejection of transplanted organs, tissues or cells; particularly, use of Met-RANTES together with cyclosporin A to produce pharmaceutical composition for treatment of renal allograft transplant rejection |
| 06/07/2005 | US6902721 Inhibitors of proteasomal activity for stimulating bone growth |
| 06/07/2005 | CA2186039C New oral pharmaceutical dosage form |
| 06/07/2005 | CA2105529C Composition comprising non-steroidal anti-inflammatory agent and effectively non-antibacterial tetracycline |
| 06/07/2005 | CA2068790C Antiviral compounds |
| 06/02/2005 | WO2005050215A1 Selection of lactic acid bacteria enhancing the immune response against streptococcus pneumoniae |
| 06/02/2005 | WO2005049827A2 Ppmp as a ceramide catabolism inhibitor for cancer treatment |
| 06/02/2005 | WO2005049142A2 Graduated estrogen contraceptive |
| 06/02/2005 | WO2005049088A2 Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent |
| 06/02/2005 | WO2005049065A2 Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
| 06/02/2005 | WO2005049060A1 Composition and method for treatment of acne |
| 06/02/2005 | WO2005049058A1 Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases |
| 06/02/2005 | WO2005049049A1 Therapeutic peg solution concentrate |
| 06/02/2005 | WO2005049047A1 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis |
| 06/02/2005 | WO2005049043A1 Combination therapy comprising metformin and anticonvulsant agents |
| 06/02/2005 | WO2005049042A1 Combinations comprising ampa receptor antagonists for the treatment of tinnitus |
| 06/02/2005 | WO2005049041A1 Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders |
| 06/02/2005 | WO2005049040A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
| 06/02/2005 | WO2005049039A1 Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders |
| 06/02/2005 | WO2005049030A1 Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |